Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: I’m staying with the herd mentality!

August 27, 2018 8:57pm

… Until late Wednesday, early Thursday and definitely by Friday

It’s an honor to be considered the “canary in the (sectors) coal mine”! I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!

When is it wrong to be right so often? Your portfolio should be profiting from RMi’s analysis!

Henry’omics:

The sector experienced a lot of headwinds …

Welcome to the short version, stocks jumped on Monday as the United States and Mexico closed a new trade deal, potentially removing a source of uncertainty that had been plaguing investors for months.

Wellfleet and Truro are wonderful; the sun is hot and the a/c is a welcome respite layered by extremely chilled Rose!

From the pre-open newsletter: “What is fair game in this market?

I question how many sessions does the sector have to run with and in this market, noting that equities are benefiting from a typically slow time in the year. Can we call it – seasonally safety – as in my case and others known to me, we are at the furthest of Cape Cod while friends (in the business) brothers and family are in Maine and New Hampshire!

Of the 45 companies covered on Monday; 7 downside equities finished in a range of -1.32% (KOOL) to -9.59% (BSTG) while the 35 upside equities oscillated from +0.19% (VYGR) to +16.23% (ALNY) with 3 flat closes (AST, ONVO and FATE).

Daily analytics and metrics:

The Dow closed up +259.29 points or +1.01%
The S&P closed up +22.05 or +0.77% to 2,986.74
The NASDAQ closed up +71.92 points or +0.91% to8, 017.90

The advance/decline line scenario of 45 covered companies:

The open was positive with an A/DL of 37/7 and 1 flat;
The mid-day continued positive with an A/DL of 34/10 and 1 flat;
The close was positive with an A/DL of 35/7 and 3 flats;

The five (5) largest trend lines: ALNY, VSTM, MDXG, IONS and SGMO

… The greatest volume to the downside: VCEL, ADVM, BLFS, KOOL and FIXX

… Upside volume was weighted to: ALNY, VSTM, MDXG, IONS and SGMO

… Leadership ($) to the downside: RENE.L (-$3.00), BLFS (-$1.27), VCEL (-$0.70), FIXX (-$0.38) and BSTG (-$0.35)

… Best moves ($) to the upside: ALNY (+$15.72), BLUE (+$6.30), IONS (+$3.90), SAGE (+$3.16) and RARE (+$2.69)

The iShares NASDAQ Biotechnology (IBB) closed:

Monday was up +1.75%;
Friday was up +0.17 %
Thursday was down -0.58%
Wednesday was up +0.71%
Tuesday was up +0.93%
Last Monday was down -0.17%

August sessions:

Monday closed POSITIVE with 7 decliners, 35 advancers and 3 flats;

Friday closed POSITIVE with 19 decliners, 24 advancers and 2 flats;

Thursday closed NEGATIVE with 26 decliners, 16 advancers and 3 flats;

Wednesday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Tuesday closed POSITIVE with 9 decliners, 36 advancers and 0 flat;

Monday closed POSITIVE with 16 decliners, 23 advancers and 6 flat;

Friday closed POSITIVE with 18 decliners, 24 advancers and 3 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Wednesday closed NEGATIVE with 36 decliners, 6 advancers and 3 flat;

Tuesday closed POSITIVE with 13 decliners, 28 advancers and 4 flat;

Monday closed NEGATIVE with 24 decliners, 19 advancers and 2 flat;

Friday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Wednesday closed NEGATIVE with 25 decliners, 16 advancers and 4 flat;

Tuesday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Monday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Friday closed NEGATIVE with 37 decliners, 4 advancers and 4 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Last Wednesday (8/1) closed NEGATIVE with 23 decliners, 21 advancers and 1 flat;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.